文献速递泌尿生殖神经技术与安全MR

新型钆基MRI对比剂钆夸曲胺在雌性食蟹猴体内的药代动力学、排泄与器官分布

Pharmacokinetics, Excretion, and Organ Distribution of the Novel Gadolinium-Based MRI Contrast Agent Gadoquatrane in Female Cynomolgus Monkeys.
PubMed 文献 · Invest Radiol · 2025-12-01

本研究在8只雌性食蟹猴中比较钆夸曲胺与钆布醇、钆特酸类似物的药代动力学,钆夸曲胺呈三室模型,有效半衰期约1.0小时,24小时尿排泄平均97%,组织残留极低且与对照品相似。

要点

  • 钆夸曲胺血浆清除快,有效半衰期约1.0小时,主要经肾排泄,24小时尿回收平均97%。
  • 给药后第5天肾皮质钆浓度最高(41 nmol Gd/g组织),皮肤低100倍、脑组织低1000倍。
  • 第5至58天各组织钆浓度大幅下降,未观察到代谢降解,与对照品结果相似。

核心结论

  • 钆夸曲胺药代动力学特征与宏环类对照品高度相似,本研究未提示其组织钆滞留风险高于对照品,代谢稳定性得到确认。

研究设计与样本

  • 动物药代动力学研究,纳入8只雌性食蟹猴,其中6只单次静脉注射等剂量(0.1 mmol镧系元素/kg体重)的钆夸曲胺、镝-布醇和铽-DOTA混合物,2只接受安慰剂,采血、排泄物及组织样本至给药后58天,采用电感耦合等离子体质谱测定浓度。

诊断标准与关键数值

  • 钆夸曲胺血浆浓度呈三相下降:分布相(α相)半衰期约3分钟,主要消除相(β相)半衰期约60分钟,缓慢终末消除相(γ相)半衰期约25小时。
  • 有效半衰期约1.0小时,总血浆清除率0.11 L/kg/h,分布容积0.17 L/kg。
  • 给药后24小时内平均97%的剂量(标准差5.3%)经尿回收,第58天仍有极少量排泄(0.01%剂量/天)。
  • 第5天组织钆浓度均低于110 ppm剂量/g组织,第58天低于10 ppm剂量/g组织;第5天肾皮质浓度最高,为41 nmol Gd/g组织。
  • 第5天皮肤钆浓度较肾皮质低100倍,选定脑区低1000倍;第5至58天所有受检组织钆浓度大幅下降。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Gadoquatrane is a tetrameric, macrocyclic, extracellular gadolinium-based MRI contrast agent with high relaxivity and stability, which is currently in Phase 3 clinical development. The aim of the present study was to characterize the pharmacokinetic profile of gadoquatrane in an animal species closely related to humans and to compare this profile with the profiles of the 2 long-established gadolinium-based contrast agents gadobutrol and gadoterate (Gd-DOTA) or, more precisely, with analogs of these agents. Non-Gd-based lanthanide analogs were used instead of the Gd-based versions to make the 3 co-injected compounds analytically differentiable.

MATERIALS AND METHODS: Eight female cynomolgus monkeys were included. Six animals received a single intravenous injection of a mixture containing gadoquatrane, Dy-butrol and Tb-DOTA at the same dose (0.1 mmol lanthanide/kg body weight). Two control animals received placebo. Procedures included collection of blood, excreta, and selected tissue samples up to 58 days post dose. Inductively coupled plasma mass spectrometry was used to measure the concentrations of the lanthanide complexes in all samples. Lanthanide plasma concentrations were fitted to a 3-compartment model to obtain pharmacokinetic parameters. High-performance liquid chromatography connected to inductively coupled plasma mass spectrometry or high-resolution mass spectroscopy was used for metabolite profiling of gadoquatrane.

RESULTS: After the injection, gadoquatrane plasma concentrations decreased in 3 phases: a distribution phase (α-phase; half-life: ~3 min), a major elimination phase (β-phase; half-life: ~60 min), and a slow terminal elimination phase (γ-phase; half-life: approximately 25 h). The effective half-life was ~1.0 hour, the total plasma clearance was 0.11 L/kg/h, and the volume of distribution was 0.17 L/kg. Gadoquatrane was rapidly and almost exclusively renally excreted. On average, 97% of the dose (SD: 5.3%) was recovered in urine within the first 24 hours after the injection. Urinary excretion was still ongoing at day 58, albeit in very small quantities (0.01% of dose/day). Only minimal amounts of Gd were detected in organ and tissue samples (<110 ppm dose/g tissue at day 5 and <10 ppm dose/g tissue at day 58). The highest concentration was found in the kidney cortex at day 5 (41 nmol Gd/g tissue). The Gd concentrations in skin and selected brain sections were lower by a factor of 100 or 1000, respectively, at day 5. Gd tissue concentrations declined substantially in all tested tissues between day 5 and day 58. Similar results were obtained for Dy-butrol and Tb-DOTA. Metabolic degradation of gadoquatrane was not observed.

CONCLUSIONS: Gadoquatrane showed a pharmacokinetic profile very similar to that of macrocyclic comparator products. There were no indications of an increased risk of a prolonged presence of gadolinium in tissues in this study after administration of gadoquatrane compared with the comparator products. Metabolite profiling confirmed the metabolic stability of gadoquatrane.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Guenther C, Frenzel T, Rottmann A, et al. Pharmacokinetics, Excretion, and Organ Distribution of the Novel Gadolinium-Based MRI Contrast Agent Gadoquatrane in Female Cynomolgus Monkeys. Invest Radiol. 2025. PMID: 40495655. doi:10.1097/RLI.0000000000001211

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。